Related Experiment Videos
HILDA/LIF urinary excretion during acute kidney rejection
J L Taupin1, D Morel, J F Moreau
1Laboratoire d'Immunologie, Fondation Bergonié, Bordeaux, France.
Transplantation
|March 1, 1992
Summary
Researchers found human interleukin for DA cells (HILDA/LIF) in the urine of kidney transplant patients experiencing acute rejection. This lymphokine was not detected in stable patients, suggesting a role in immune responses.
Area of Science:
- Immunology
- Molecular Biology
- Nephrology
Background:
- Human interleukin for DA cells (HILDA/LIF) is a newly described lymphokine.
- HILDA/LIF is identical to several previously identified factors, including leukemia inhibitory factor.
- This cytokine exhibits diverse effects on various cell types and biological processes.
Purpose of the Study:
- To investigate the presence of HILDA/LIF in kidney graft recipients.
- To determine if HILDA/LIF levels correlate with acute rejection episodes or stable graft function.
Main Methods:
- Detection of HILDA/LIF in serum and urine samples from kidney transplant recipients.
- Comparison of HILDA/LIF levels between patients with acute rejection and those with stable renal function.
Main Results:
- HILDA/LIF was detected in the urine of kidney graft recipients during acute rejection episodes.
- HILDA/LIF was not detected in the serum of these patients.
- The lymphokine was undetectable in both serum and urine of patients with stable renal function.
Conclusions:
- The findings suggest a potential role for HILDA/LIF in the inflammatory and immune responses associated with kidney transplant rejection.
- HILDA/LIF may serve as a biomarker for monitoring kidney allograft status.